Dyax Corporation (DYAX)
  • Россия
  • Украина

Dyax Corporation (DYAX)

Contact Details

55 Network Dr, Burlington, Massachusetts, USA 01803-2756
(617) 225-2500
55 Network Dr, Burlington, Massachusetts, USA 01803-2756

General Information

Dyax Corp is a biopharmaceutical company that has developed and patented a method that is used to identify a broad range of compounds with potential for the treatment and diagnosis of diseases. The company is also using this method to identify compounds that could be used in purifying and manufacturing biopharmaceuticals and other chemicals. The company`s phage display technology to rapidly and cost-effectively determine the potential medical uses of newly discovered proteins and genes and subsequently discover biopharmaceutical product candidates.

Contact Information

Phone(617) 225-2500
Website 1http://www.dyax.com
Thomson Reuters PermID4295900974


NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO and President$3,604,9482014113.3%
CFO and Executive VP$1,793,9922014125.3%
Executive VP and Other Executive Officer$1,527,5052014
Executive VP and General Counsel$1,742,6642014116.0%
Chief Medical Officer and Divisional Executive VP$2,576,932201453.8%

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
Department of Veterans AffairsDrugs and BiologicalsJune 23, 2010$40,151.16
Department of Veterans AffairsDrugs and BiologicalsMarch 09, 2010$0

Corporate Data


  • Pharmaceutical Preparation Manufacturing
  • Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

SIC Industries

  • Pharmaceutical Preparations
  • Biological Research

Company Size

Sales Volume$81.7 million


Ticker SymbolDYAX
ExchangeNASDAQ Global Market
Type of EntityFor Profit Organization
Type of OwnershipNot Tax Exempt Corporate Entity
Federal AwardsReceives Contracts
Year Founded1989


Previous Close38.31
Bid38.40 x 17,100
Ask38.41 x 3,200
Day`s Range38.25 - 38.56
52-Week Range13.55 - 37.74
Average Volume (1M)2,025,267
Market Cap.$5,537.1 Million
Last Dividend Amount0
1y Target Price Est.32.4


Period EndingSep. 30, 2015Jun. 30, 2015Mar. 31, 2015Dec. 31, 2014
Total Revenue24,72926,37320,41826,028
Cost of Revenue3,5643,6153,7833,102
Gross Profit21,16522,75816,63522,926
Research Development15,62414,51010,24212,349
Selling General and Administrative14,03314,15311,04110,233
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses33,22132,27825,06625,684
Other Income/Expenses Net----
Earnings Before Interest and Taxes(8,492)(5,905)(4,648)344
Interest Expense3,4262,7092,7112,716
Income Before Tax(11,701)(8,411)(7,271)(2,290)
Income Tax Expense----
Minority Interest----
Net Income from Continuing Ops(11,701)(8,411)(7,271)(2,290)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income(11,701)(8,411)(7,271)(2,290)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares(11,701)(8,411)(7,271)(2,290)